News & Events
Bilthoven, The Netherlands
Sapreme, a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD). Additionally, the company has established its Scientific Advisory Board (SAB), comprised of experts in diseases with high unmet medical need, as well as the rapidly expanding field of RNA delivery. Read the full press release here.
Upcoming Events
No events scheduled ahead
About Sapreme:
Sapreme is a preclinical-stage biotech company developing next-generation RNA therapeutics for patients with genetically driven diseases. Our proprietary endosomal escape technology enables targeted delivery of large molecules such as ASOs and siRNAs to intracellular targets in liver and extrahepatic tissues.
For Media Inquiries, please contact:
Trophic Communications
Desmond James or Valeria Fisher | +49 151 67859086 or +49 175 8041816 | sapreme@trophic.eu